Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37793771

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Haematol
Publication date
2023 Oct
First author
Dimopoulos MA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2023 Oct;10(10):e786-e787. doi: 10.1016/S2352-3026(23)00278-8.
    note
    Source null
    related pmid
    37793761
    relationship
    Comment in

Authors and identifiers

  1. name
    Dimopoulos MA
    type
    Author
  2. name
    Hungria VTM
    type
    Author
  3. name
    Radinoff A
    type
    Author
  4. name
    Delimpasi S
    type
    Author
  5. name
    Mikala G
    type
    Author
  6. name
    Masszi T
    type
    Author
  7. name
    Li J
    type
    Author
  8. name
    Capra M
    type
    Author
  9. name
    Maiolino A
    type
    Author
  10. name
    Pappa V
    type
    Author
  11. name
    Chraniuk D
    type
    Author
  12. name
    Osipov I
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Dimopoulos MA
    type
    Author
  2. name
    Hungria VTM
    type
    Author
  3. name
    Radinoff A
    type
    Author
  4. name
    Delimpasi S
    type
    Author
  5. name
    Mikala G
    type
    Author
  6. name
    Masszi T
    type
    Author
  7. name
    Li J
    type
    Author
  8. name
    Capra M
    type
    Author
  9. name
    Maiolino A
    type
    Author
  10. name
    Pappa V
    type
    Author
  11. name
    Chraniuk D
    type
    Author
  12. name
    Osipov I
    type
    Author
bibliography ids
  1. nci-bib-3ae2c8bf6c11ad34f6239e1a
book metadata
content sha256
1566d02474d97a425889c0a76c79e439980903de82c2e67a5eae3ab8ec295975
document type
citation
dois
  1. 10.1016/S2352-3026(23)00243-0
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:37793771
immutable id
pubmed:37793771@1566d02474d97a425889c0a76c79e439980903de82c2e67a5eae3ab8ec295975
journal
abbreviation
Lancet Haematol
issn electronic
2352-3026
issn print
Source null
issue
10
name
The Lancet. Haematology
nlm unique id
101643584
pages
e801-e812
volume
10
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2023 Oct;10(10):e786-e787. doi: 10.1016/S2352-3026(23)00278-8.
    note
    Source null
    related pmid
    37793761
    relationship
    Comment in
outcomes validated
false
pmid
37793771
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
9957cac29b5530638b44fa7652659832a80cfc6db11fa8dd44cdac4ed153110b
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Oct
precision
month
year
2023
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37793771/
title
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.

Preserved source evidence · Not medical advice